Prestige Consumer Healthcare Inc.: Form 10-Q for the period ended Dec 31, 2023
Filed with the SEC on Feb 8, 2024 and accepted by EDGAR at Feb 8, 2024, 06:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-10-01 to 2023-12-31 | $282.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-04-01 to 2023-12-31 | $848.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-10-01 to 2023-12-31 | $124.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2023-04-01 to 2023-12-31 | $375.7m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-10-01 to 2023-12-31 | $157.9m | us-gaap:GrossProfit |
| Gross profit | 9 months2023-04-01 to 2023-12-31 | $472.6m | us-gaap:GrossProfit |
| Operating income | 3 months2023-10-01 to 2023-12-31 | $86.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-04-01 to 2023-12-31 | $260.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-10-01 to 2023-12-31 | $16.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-04-01 to 2023-12-31 | $48.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-10-01 to 2023-12-31 | $53.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-04-01 to 2023-12-31 | $159.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-10-01 to 2023-12-31 | $1.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-04-01 to 2023-12-31 | $3.19 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-10-01 to 2023-12-31 | $1.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-04-01 to 2023-12-31 | $3.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-10-01 to 2023-12-31 | 50,125,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-04-01 to 2023-12-31 | 50,134,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-04-01 to 2023-12-31 | $182.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-04-01 to 2023-12-31 | $6.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2023-04-01 to 2023-12-31 | $25.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-12-31 | $63.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $393.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $3.34bn | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $127.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $1.74bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-12-31 | $1.21bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2023-12-31 | $1.60bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001295947-24-000008. Last ingested by Listed: Nov 5, 2026, 11:26 ET. Listed shows no prices and gives no investment advice.